This is a commercial expansion deal with no disclosed financial terms. Monitor for future revenue disclosures or additional clinical data from the INI study that could support payer reimbursement. The stock's micro-cap status means even small contract wins can move the price, but the lack of hard numbers limits near-term catalyst potential.
Price Chart
Executive Summary
Aclarion announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expand availability of its Nociscan platform for chronic low back pain diagnosis. The deal includes a real-world evidence study comparing Nociscan's chemical biomarker data with SPECT-CT bone metabolic information, supporting Aclarion's scalable growth strategy and payer/provider adoption efforts.
Key Facts
- Agreement with Institute of Neuro Innovation (INI) in Los Angeles to bring Nociscan to the clinic led by neurosurgeon Amir Vokshoor, MD.
- INI will generate real-world evidence comparing Nociscan chemical biomarker data with SPECT-CT bone metabolic information.
- Nociscan is a SaaS platform that noninvasively helps physicians distinguish painful from nonpainful lumbar discs using MRS and AI.
- Nociscan claims a 97% surgical success rate when all Nociscan-positive discs are treated.
- Chronic low back pain affects approximately 266 million people worldwide.
Financial Impact
No financial terms of the agreement were disclosed.
Risk Factors
- No financial terms disclosed — deal may be small or non-revenue generating initially.
- Real-world evidence study may not produce favorable results or timely data.
- Aclarion has a micro-cap market cap of $9M, making it highly volatile and sensitive to dilution or liquidity events.
- Competition from established diagnostic tools like MRI and SPECT-CT may limit adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305854 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | Insider Cluster | $2.77 $2.64 | ▼ −4.69% | ▼ −2.74% | $1.97 (−28.75%) |
Aug 18, 2026 9w ago | Insider Cluster | $2.60 $2.53 | ▼ −2.67% | ▼ −1.68% | $1.97 (−24.10%) |
Jun 9, 2026 19w ago | Press Release | $3.26 $2.99 | ▼ −8.28% | ▼ −9.73% | $1.97 (−39.46%) |
Jun 8, 2026 20w ago | Press Release | $3.36 $3.07 | ▼ −8.63% | ▼ −10.26% | $1.97 (−41.26%) |
Jun 3, 2026 20w ago | Press Release | $3.49 $3.09 | ▼ −11.46% | ▼ −10.46% | $1.97 (−43.45%) |
Jun 1, 2026 21w ago | Press Release | $3.37 $2.88 | ▼ −14.54% | ▼ −13.24% | $1.97 (−41.44%) |
May 6, 2026 24w ago | Insider Cluster | $3.28 $3.49 | ▲ +6.40% | ▲ +3.62% | $1.97 (−39.83%) |
May 5, 2026 24w ago | Press Release | $3.20 $3.50 | ▲ +9.38% | ▲ +4.42% | $1.97 (−38.33%) |
Apr 22, 2026 26w ago | Press Release | $3.73 $3.20 | ▼ −14.21% | ▼ −17.37% | $1.97 (−47.09%) |
Mar 19, 2026 31w ago | Press Release | $3.26 $3.39 | ▲ +3.99% | ▼ −3.63% | $1.97 (−39.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers